Disease · MONDO_0005504
diphtheria
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. diphtheria. Diseases, record MONDO_0005504. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005504
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TETANUS TOXOID | CHEMBL2108875 | Vaccine component | Approval | TTD | 3 | 2 | 2 | Drugs and targets |
| BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ | CHEMBL6068348 | Vaccine component | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| BORDETELLA PERTUSSIS PERTACTIN AUTOTRANSPORTER | CHEMBL6068350 | Vaccine component | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| DIPHTHERIA TOXOID | CHEMBL2109121 | Vaccine component | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN | CHEMBL4297973 | Vaccine component | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| PENTETIC ACID | CHEMBL780 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| TECHNETIUM TC 99M PENTETATE | CHEMBL2096656 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| TRALOKINUMAB | CHEMBL1743081 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| IL13 | Interleukin-13 | 1 | Interleukin-13 inhibitor | Phase 2 | https://conductscience.org/library/genes/3596 |
Source Drugs and targets
Trials3
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02853929 | Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery | Phase 4 | 551 | 2020-01-14 | Diphtheria, Hepatitis B, Acellular Pertussis, Haemophilus Influenzae Type b, Tetanus, Poliomyelitis, Diphtheria-Tetanus-aPertussis-Hepatitis B-Poliomyelitis-Haemophilus Influenzae Type b Vaccines | BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ, BORDETELLA PERTUSSIS PERTACTIN AUTOTRANSPORTER, DIPHTHERIA TOXOID, HEPATITIS B VIRUS HBSAG SURFACE PROTEIN ANTIGEN, TETANUS TOXOID | Its record names the disease | ClinicalTrials.gov |
| NCT00304265 | Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine | Phase 4 | 215 | 2011-04-07 | Pertussis, Diphtheria, Tetanus, Poliomyelitis | TETANUS TOXOID | Its record names the disease | ClinicalTrials.gov |
| NCT03562377 | Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) | Phase 2 | 215 | 2021-03-05 | Atopic Dermatitis | TRALOKINUMAB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials11
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| dTpa Group vs Control Group: Number of Subjects With Unsolicited Adverse Events (AEs) | 94 of 263 | 111 of 277 | 540 | NCT02853929 | Trial comparisons |
| dTpa Group vs Control Group: Number of Subjects With Serious Adverse Events (SAEs) | 0 of 263 | 3 of 277 | 540 | NCT02853929 | Trial comparisons |
| dTpa Group vs Control Group: deaths from any cause | 0 of 263 | 0 of 277 | 540 | NCT02853929 | Trial comparisons |
| dTpa Group vs Control Group: serious adverse events | 0 of 263 | 3 of 277 | 540 | NCT02853929 | Trial comparisons |
| 6th Dose Pertussis Vaccine Group vs 5th Dose Pertussis Vaccine Group: serious adverse events | 0 of 117 | 0 of 98 | 215 | NCT00304265 | Trial comparisons |
| Tralokinumab vs Placebo: Participants With Investigator's Global Assessment (IGA) Score of 0 (Clear) or 1 (Almost Clear) at Week 16 | 33 of 106 | 21 of 108 | 214 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: Participants Achieving at Least 75% Reduction in Eczema Area and Severity Index (EASI) at Week 16. | 52 of 106 | 39 of 108 | 214 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: deaths from any cause | 1 of 107 | 0 of 107 | 214 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: serious adverse events | 3 of 107 | 3 of 107 | 214 | NCT03562377 | Trial comparisons |
| Tralokinumab vs Placebo: Positive Anti-tetanus Response at Week 16 | 80 of 87 | 73 of 76 | 163 | NCT03562377 | Trial comparisons |
1 to 10 of 11
See all 11 comparisons in its trialsPapers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005504
GET https://conductscience.org/api/diseases/v1/MONDO_0005504/drugs